Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549495 | 0.81 | KDM4E (0.49) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12987546 | 0.78 | KDM4E (0.49) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12987397 | 0.78 | KDM4E (0.51) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12987766 | 0.77 | USP2 (0.49) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL11481100 | 0.74 | KDM4E (0.48) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12987924 | 0.72 | AURKA (0.52) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12987742 | 0.72 | MAT2A (0.47) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL23869757 | 0.71 | APOBEC3G (0.57) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL30166499 | 0.71 | APOBEC3G (0.57) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12631906 | 0.70 | ALDH1A1 (0.45) | KDM4ENPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855214-B2 | Fused cyclic systems useful as inhibitors of TEC family protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209255-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K1 | KDM4E 2232/4885NPC1 2378/4885RAB9A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.